Eyepoint Signs New Agreement for Expanded Access of DEXYCU within America’s largest Integrated Delivery Systems
Eyepoint Pharmaceuticals (NASDAQ: EYPT), a speciality biopharmaceutical Company engaged in developing ophthalmic solutions for the treatment of eye diseases, announced the signing of a two-year contract with one of the largest integrated delivery systems in the U.S to offer DEXYCU within its network, along with...
